{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:47:46Z","timestamp":1773938866077,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,6]],"date-time":"2027-02-06T00:00:00Z","timestamp":1801872000000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society Inc","doi-asserted-by":"publisher","award":["ACS RSG-22\\u2013105-01-CSCT"],"award-info":[{"award-number":["ACS RSG-22\\u2013105-01-CSCT"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.urology.2025.11.251","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T17:27:03Z","timestamp":1764955623000},"page":"24-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Can Novel Biomarkers Augment Traditional Surveillance Paradigms in Early-stage Testicular Germ Cell Tumors? A Case Study in Pre-clinical Relapse Detection Using a Combination Micro-RNA-371a-3p and 372-3p Assay"],"prefix":"10.1016","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2257-3859","authenticated-orcid":false,"given":"Jonathan","family":"Huynh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Knezevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Sheinfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisa","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel A.","family":"Funt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0757-0885","authenticated-orcid":false,"given":"Richard S.","family":"Matulewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2025.11.251_bib1","first-page":"623","article-title":"Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009","volume":"33","author":"Nigam","year":"2015","journal-title":"World J\u00a0Urol"},{"key":"10.1016\/j.urology.2025.11.251_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1620\/tjem.252.219","article-title":"Trends in age and histology of testicular cancer from 1980-2019: a single-center study","volume":"252","author":"Yamashita","year":"2020","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.urology.2025.11.251_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1748-717X-6-90","article-title":"Pure seminoma: a review and update","volume":"6","author":"Boujelbene","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.urology.2025.11.251_bib4","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1002\/cam4.3837","article-title":"Screening for cancers with a good prognosis: the case of testicular germ cell cancer","volume":"10","author":"Heijnsdijk","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.urology.2025.11.251_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/jnci\/djq535","article-title":"Stage I seminoma: adjuvant treatment is effective but is it necessary?","volume":"103","author":"Chung","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.urology.2025.11.251_bib6","author":"Gilligan","year":"2025","journal-title":"NCCN Guidelines\u00ae Insights: Testicular Cancer, Version 2. 2025"},{"key":"10.1016\/j.urology.2025.11.251_bib7","first-page":"20","article-title":"Diagnosis and treatment of early-stage testicular cancer: AUA Guideline Amendment 2023","volume":"211","author":"Stephenson","year":"2024","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2025.11.251_bib8","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3390\/cancers16071379","article-title":"Advancing GCT management: a review of miR-371a-3p and other miRNAs in comparison to traditional serum tumor markers","volume":"16","author":"Seales","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.urology.2025.11.251_bib9","first-page":"51","article-title":"Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance","volume":"33","author":"Kollmannsberger","year":"2015","journal-title":"J\u00a0Clin\u00a0Oncol\u00a0Offl J\u00a0Am\u00a0Soc\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.urology.2025.11.251_bib10","first-page":"2277","article-title":"Computed tomography\u2014an increasing source of radiation exposure","volume":"357","author":"Brenner","year":"2007","journal-title":"N\u00a0Eng\u00a0J\u00a0Med"},{"key":"10.1016\/j.urology.2025.11.251_bib11","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4065\/mcp.2010.0260","article-title":"Radiation risk from medical imaging","volume":"85","author":"Lin","year":"2010","journal-title":"Mayo Clin\u00a0Proc"},{"key":"10.1016\/j.urology.2025.11.251_bib12","first-page":"2468","article-title":"Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: results from a randomized, Phase III, noninferiority trial (TRISST)","volume":"40","author":"Joffe","year":"2022","journal-title":"J\u00a0Clin\u00a0Oncol\u00a0Offl J\u00a0Am\u00a0Soc\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.urology.2025.11.251_bib13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(04)15433-0","article-title":"Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries","volume":"363","author":"Berrington de Gonz\u00e1lez","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2025.11.251_bib14","series-title":"Radiation risks from medical X-ray examinations as a function of the age and sex of the patient","author":"Wall","year":"2011"},{"key":"10.1016\/j.urology.2025.11.251_bib15","first-page":"5451","article-title":"An overview of microRNAs: biology, functions, therapeutics, and analysis methods","volume":"234","author":"Saliminejad","year":"2019","journal-title":"J\u00a0Cell\u00a0Physiol"},{"key":"10.1016\/j.urology.2025.11.251_bib16","doi-asserted-by":"crossref","first-page":"9189","DOI":"10.1038\/s41598-019-45573-6","article-title":"miRNA-302s may act as oncogenes in human testicular germ cell tumours","volume":"9","author":"Das","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.urology.2025.11.251_bib17","first-page":"1","article-title":"Perioperative serum microRNA 371a-3p and 372-3p levels in patients with clinically localized testicular masses","volume":"68","author":"Matulewicz","year":"2024","journal-title":"Eur\u00a0Urol\u00a0Open Sci"},{"key":"10.1016\/j.urology.2025.11.251_bib18","first-page":"867","article-title":"Analytical validation and performance characteristics of molecular serum biomarkers, miR-371a-3p and miR-372-3p, for male germ cell tumors, in a clinical laboratory setting","volume":"24","author":"Ye","year":"2022","journal-title":"J\u00a0Mol\u00a0Diagn JMD"},{"key":"10.1016\/j.urology.2025.11.251_bib19","first-page":"137","article-title":"Real-world application of pre-orchiectomy miR-371a-3p test in testicular germ cell tumor management","volume":"205","author":"Badia","year":"2021","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2025.11.251_bib20","first-page":"1412","article-title":"Serum levels of MicroRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study","volume":"37","author":"Dieckmann","year":"2019","journal-title":"J\u00a0Clin\u00a0Oncol\u00a0Offl J\u00a0Am\u00a0Soc\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.urology.2025.11.251_bib21","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.euf.2022.04.008","article-title":"Circulating MicroRNAs for detection of germ cell tumours: a narrative review","volume":"8","author":"Fankhauser","year":"2022","journal-title":"Eur Urol Foc"},{"key":"10.1016\/j.urology.2025.11.251_bib22","first-page":"3090","article-title":"Developing a highly specific biomarker for germ cell malignancies: plasma miR371 expression across the germ cell malignancy spectrum","volume":"37","author":"Nappi","year":"2019","journal-title":"J\u00a0Clin\u00a0Oncol\u00a0Offl\u00a0J\u00a0Am\u00a0Soc\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.urology.2025.11.251_bib23","article-title":"DigiMir test: establishing a novel pipeline for MiR-371a quantification using droplet digital PCR in liquid biopsies from testicular germ cell tumor patients","volume":"12","author":"Sequeira","year":"2022","journal-title":"Front\u00a0Oncol"},{"key":"10.1016\/j.urology.2025.11.251_bib24","first-page":"1140","article-title":"Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours","volume":"126","author":"Fankhauser","year":"2022","journal-title":"Br\u00a0J\u00a0Cancer"},{"key":"10.1016\/j.urology.2025.11.251_bib25","doi-asserted-by":"crossref","first-page":"20170338","DOI":"10.1098\/rstb.2017.0338","article-title":"Germ cell tumour subtypes display differential expression of microRNA371a-3p","volume":"373","author":"Vilela-Salgueiro","year":"2018","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.urology.2025.11.251_bib26","doi-asserted-by":"crossref","first-page":"5447","DOI":"10.3390\/cancers14215447","article-title":"Testicular neoplasms: primary tumour size is closely interrelated with histology, clinical staging, and tumour marker expression rates-a comprehensive statistical analysis","volume":"14","author":"Dieckmann","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.urology.2025.11.251_bib27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s13402-017-0333-9","article-title":"microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients","volume":"40","author":"van Agthoven","year":"2017","journal-title":"Cell Oncol"},{"key":"10.1016\/j.urology.2025.11.251_bib28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000477446","article-title":"Serum levels of MicroRNA371a-3p: a highly sensitive tool for diagnosing and staging testicular germ cell tumours: a clinical case series","volume":"99","author":"Anheuser","year":"2017","journal-title":"Urol Int"},{"key":"10.1016\/j.urology.2025.11.251_bib29","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1078-0432.CCR-23-0730","article-title":"Detection of recurrence through microRNA-371a-3p serum levels in a follow-up of Stage I testicular germ cell tumors in the DRKS-00019223 study","volume":"30","author":"Belge","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2025.11.251_bib30","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bju.16644","article-title":"Comparison of serum and plasma microRNA expression levels in patients with germ cell tumours","volume":"135","author":"Baky","year":"2025","journal-title":"BJU Int"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525013378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525013378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:28:04Z","timestamp":1773934084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429525013378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":30,"alternative-id":["S0090429525013378"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2025.11.251","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can Novel Biomarkers Augment Traditional Surveillance Paradigms in Early-stage Testicular Germ Cell Tumors? A Case Study in Pre-clinical Relapse Detection Using a Combination Micro-RNA-371a-3p and 372-3p Assay","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2025.11.251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}